Clinical trial
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or…
NCT00245362 · Cell Genesys, Industry · Completed
Key facts
| NCT number | NCT00245362 |
|---|---|
| Title | A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer |
| Official title | A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer |
| Lead sponsor | Cell Genesys, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Cancer, Nonresectable Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | CG 8020 and CG 2505 |
| Enrollment | 50 |
| Start date | Jun 1, 2002 |
| Completion | Jun 1, 2004 |
| First posted | Oct 28, 2005 |
| Last update posted | Oct 28, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: